Recent Analysts’ Ratings Updates for Gilead Sciences (GILD)

Several brokerages have updated their recommendations and price targets on shares of Gilead Sciences (NASDAQ: GILD) in the last few weeks:

• 8/15/2026 – Gilead Sciences was upgraded by Wall Street Zen from “hold” to “buy”.
• 8/11/2026 – Gilead Sciences was downgraded by Weiss Ratings from “buy (b-)” to “hold (c-)”.
• 8/5/2026 – Gilead Sciences had its price target raised by Royal Bank Of Canada from $120.00 to $123.00. They now have a “sector perform” rating on the stock.
• 8/5/2026 – Gilead Sciences had its “overweight” rating reaffirmed by Cantor Fitzgerald. They now have a $155.00 price target on the stock.
• 8/5/2026 – Gilead Sciences had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $170.00 price target on the stock.
• 8/1/2026 – Gilead Sciences was downgraded by Wall Street Zen from “buy” to “hold”.
• 7/29/2026 – Gilead Sciences had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 7/29/2026 – Gilead Sciences had its price target lowered by Barclays PLC from $155.00 to $145.00. They now have an “equal weight” rating on the stock.
• 7/27/2026 – Gilead Sciences had its price target lowered by Morgan Stanley from $166.00 to $165.00. They now have an “overweight” rating on the stock.
• 7/21/2026 – Gilead Sciences was downgraded by Leerink Partners from “outperform” to “market perform”. They now have a $127.00 price target on the stock, down from $146.00.
• 7/12/2026 – Gilead Sciences was upgraded by Wall Street Zen from “hold” to “buy”.
• 7/8/2026 – Gilead Sciences had its price target lowered by Morgan Stanley from $168.00 to $166.00. They now have an “overweight” rating on the stock.
• 7/7/2026 – Gilead Sciences had its price target lowered by Royal Bank Of Canada from $122.00 to $120.00. They now have a “sector perform” rating on the stock.
• 7/7/2026 – Gilead Sciences had its price target lowered by Truist Financial Corporation from $157.00 to $156.00. They now have a “buy” rating on the stock.
• 7/6/2026 – Gilead Sciences was upgraded by HSBC Holdings plc from “hold” to “buy”. They now have a $155.00 price target on the stock, up from $133.00.
• 7/6/2026 – Gilead Sciences had its “overweight” rating reaffirmed by Cantor Fitzgerald. They now have a $155.00 price target on the stock.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be issued a dividend of $0.82 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.4%. Gilead Sciences’s dividend payout ratio (DPR) is currently -122.85%.

Insider Activity

In related news, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $123.92, for a total value of $371,760.00. Following the transaction, the insider directly owned 124,234 shares in the company, valued at approximately $15,395,077.28. This represents a 2.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the firm’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $130.31, for a total transaction of $1,954,650.00. Following the transaction, the chief executive officer directly owned 592,133 shares in the company, valued at approximately $77,160,851.23. This represents a 2.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 51,000 shares of company stock valued at $6,568,860. 0.30% of the stock is owned by company insiders.

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.